Equilibrative Nucleoside Transporter 1
"Equilibrative Nucleoside Transporter 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A subtype of equilibrative nucleoside transporter proteins that is sensitive to inhibition by 4-nitrobenzylthioinosine.
| Descriptor ID |
D033721
|
| MeSH Number(s) |
D12.776.157.530.625.750.500.500 D12.776.157.530.937.532.500 D12.776.543.585.625.750.500.500 D12.776.543.585.937.563.500
|
| Concept/Terms |
Equilibrative Nucleoside Transporter 1- Equilibrative Nucleoside Transporter 1
- Equilibrative NBMPR-Sensitive Nucleoside Transporter
- Equilibrative NBMPR Sensitive Nucleoside Transporter
- Equilibrative Nitrobenzylmercaptopurine Riboside-Sensitive Nucleoside Transporter
- Equilibrative Nitrobenzylmercaptopurine Riboside Sensitive Nucleoside Transporter
- SLC29A1 Transporter
- Solute Carrier Family 29 (Nucleoside Transporters), Member 1
|
Below are MeSH descriptors whose meaning is more general than "Equilibrative Nucleoside Transporter 1".
Below are MeSH descriptors whose meaning is more specific than "Equilibrative Nucleoside Transporter 1".
This graph shows the total number of publications written about "Equilibrative Nucleoside Transporter 1" by people in this website by year, and whether "Equilibrative Nucleoside Transporter 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Equilibrative Nucleoside Transporter 1" by people in Profiles.
-
Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res. 2018 10 01; 24(19):4734-4744.
-
Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach. Pancreas. 2016 11; 45(10):1485-1493.